Komori
Astellas Pharma (4503) · InitiativeAchieved

Making Propella Therapeutics a Wholly Owned Subsidiary Through Acquisition

First written in FY2024-Q3. 1 of 1 entries say "Achieved", first in FY2024-Q3. Latest entry: FY2024-Q3.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Making Propella Therapeutics a Wholly Owned Subsidiary Through AcquisitionA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2024-Q3AchievedAnnual report

    「当第３四半期連結会計期間において、当社は、米国のバイオ医薬品企業であるPropella Therapeutics, Inc.との間で、同社を買収することで合意し、2023年11月に契約を締結しました。この契約に基づき、米国東部時間 2023年12月21日に同社の買収が完了し、同社を当社の完全子会社としました。」

    2023年11月に買収契約を締結し、2023年12月21日に買収を完了して完全子会社化した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.